Parkinson Disease CRISPR Cell Models for Drug Discovery

Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting approximately 1% of individuals over 60 years old globally. According to the World Health Organization (WHO), the prevalence of PD has doubled in the last 25 years, with over 8.5 million people living with the disease worldwide as of 2019. The global burden is rising due to aging populations and increased environmental exposures. PD is characterized by progressive motor symptoms (bradykinesia, rigidity, tremor) and non-motor symptoms (cognitive decline, depression, sleep disorders). There is no cure, and current therapies primarily manage symptoms. The National Cancer Institute (NCI) does not track PD, but the National Institute of Neurological Disorders and Stroke (NINDS) highlights that PD research is critical for developing disease-modifying therapies.

PD is an ideal disease for mechanistic studies due to its well-defined genetic and pathological hallmarks: alpha-synuclein aggregation, mitochondrial dysfunction, and dopaminergic neuron loss. Public datasets such as the Parkinson's Progression Markers Initiative (PPMI) and the UK Biobank provide extensive clinical and genomic data. Key open questions include the role of environmental triggers, the mechanisms of alpha-synuclein propagation, and the identification of biomarkers for early diagnosis. Gene-edited cell models are essential for dissecting these pathways in a controlled human cellular context.

PD pathogenesis involves several interconnected pathways:

• • Alpha-synuclein aggregation and proteostasis:

1. Misfolding of alpha-synuclein (SNCA) into oligomers and fibrils.

2. Accumulation in Lewy bodies and Lewy neurites.

3. Impaired autophagy-lysosomal degradation (e.g., GBA mutations).

• • Mitochondrial dysfunction:

1. Impaired complex I activity in the electron transport chain.

2. Increased reactive oxygen species (ROS) production.

3. Loss of PINK1/Parkin-mediated mitophagy.

• • Neuroinflammation:

1. Activation of microglia and astrocytes.

2. Release of pro-inflammatory cytokines (TNF-alpha, IL-6).

3. Chronic neuroinflammation exacerbates neuronal death.

• • Oxidative stress:

1. Dopamine metabolism generates ROS.

2. Reduced glutathione levels.

3. Lipid peroxidation and DNA damage.

Data from ClinVar, NCBI Gene, and COSMIC (v99).

Key signaling networks in PD:

• • Autophagy-lysosome pathway (ALP):
• • GBA mutations impair lysosomal function.
• • LRRK2 hyperactivation disrupts autophagic flux.
• • SNCA accumulation inhibits chaperone-mediated autophagy.
• • Mitochondrial quality control:
• • PINK1/Parkin pathway defects lead to mitophagy failure.
• • DJ-1 loss increases oxidative stress.
• • Complex I inhibition (e.g., by rotenone) mimics PD pathology.
• • Dopaminergic signaling:
• • Dopamine metabolism produces ROS.
• • Loss of dopamine transporters (DAT) in neurons.
• • D2 receptor signaling modulates neuroinflammation.
• • Inflammatory signaling:
• • TLR4 activation by alpha-synuclein.
• • NF-kB pathway upregulation in microglia.
• • NLRP3 inflammasome activation.

Organoids (e.g., midbrain organoids) offer 3D architecture with multiple cell types (neurons, astrocytes, microglia), enabling study of cell-cell interactions and alpha-synuclein propagation.

Common PD animal models:

• • Neurotoxin models:
• • MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in mice and primates.
• • 6-OHDA (6-hydroxydopamine) in rats.
• • Rotenone in rats.
• • Genetic models:
• • SNCA transgenic mice (A53T, A30P mutations).
• • LRRK2 G2019S knock-in mice.
• • PINK1 and Parkin knockout mice.
• • Viral vector models:
• • AAV-mediated SNCA overexpression in rats or mice.
• • Lentiviral delivery of mutant LRRK2.
• • Patient-derived xenograft (PDX) models are not standard for PD; instead, human iPSC-derived neurons are transplanted into rodent brains.

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications, providing controlled models to study PD-associated mutations. Examples include:

• • SNCA knockout lines (e.g., in SH-SY5Y or iPSC-derived neurons) to study loss-of-function effects.
• • LRRK2 G2019S knock-in lines to model the most common PD mutation.
• • GBA N370S knock-in lines to investigate lysosomal dysfunction.
• • PINK1 and PRKN knockout lines to study mitophagy defects.

These models are commercially available as sequence-verified, clonal cell lines, eliminating the need for laborious in-house editing. They enable reproducible experiments in drug screening, target validation, and mechanistic studies. Isogenic pairs (mutant vs. wild-type) are particularly valuable for identifying mutation-specific phenotypes.

Gene-edited cell models are used to validate the functional impact of PD-associated genetic variants. For example:

• • SNCA knockout in SH-SY5Y cells reduces alpha-synuclein aggregation and rescues mitochondrial function.
• • LRRK2 G2019S knock-in iPSC-derived neurons show increased kinase activity and impaired autophagy, which can be reversed by LRRK2 inhibitors.
• • PINK1 knockout cells exhibit defective mitophagy, confirming the role of PINK1 in mitochondrial quality control.

These models allow researchers to dissect the molecular pathways linking genotype to phenotype.

Isogenic cell pairs (e.g., LRRK2 G2019S vs. wild-type) are used in high-throughput screens to identify compounds that selectively target mutant cells. Examples:

• • LRRK2 kinase inhibitors (e.g., GSK2578215A) show greater efficacy in G2019S cells.
• • GBA modulators (e.g., ambroxol) are tested in GBA N370S knock-in lines.
• • Resistance mechanisms can be modeled by chronic drug exposure in gene-edited cells, revealing adaptive changes in autophagy or mitochondrial pathways.

CRISPR-based screens using gene-edited cells can identify synthetic lethal interactions and biomarkers. For example:

• • A genome-wide CRISPR knockout screen in LRRK2 G2019S cells identified genes whose loss sensitizes cells to LRRK2 inhibition, revealing potential combination therapies.
• • Secretome analysis of SNCA knockout vs. wild-type cells identifies alpha-synuclein-related biomarkers for early diagnosis.
• • Transcriptomic profiling of PINK1 knockout cells uncovers mitochondrial stress signatures that could serve as disease progression markers.